Sponsor Check › Person
Related person on Form D filings · address states/countries as listed: NJ, MO, Israel (as filed: L3), United Kingdom (as filed: X0), MD, NY, CA · listed Mar 3, 2011 → Jul 24, 2019
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:58 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this person.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
11 of 32 offerings report sales commissions totalling $3,822,950; 5 report finder's fees totalling $11,574,320; 3 report proceeds to related persons totalling $376,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Mar 14, 2024 D File 021-507589 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2023 D File 021-496373 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 8, 2023 D File 021-491704 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 14, 2022 D File 021-441778 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 11, 2022 D File 021-433189 | $0 | $295,000 | $0 The proceeds from the offering will not be used for payments to any of the persons identified as related persons in response to Item 3. | A.G.P./Alliance Global Partners BrokerCheck CRD 8361 ↗ |
| EDGAR ↗ | Apr 28, 2021 D File 021-397547 | $0 | $1,104,501 | $0 The proceeds from the offering will not be used for payments to any of the persons identified as related persons in response to Item 3. | A.G.P./Alliance Global Partners BrokerCheck CRD 8361 ↗ |
| EDGAR ↗ | Jan 29, 2020 D File 021-359236 | $739,200 | $0 | $0 | Mio Capital Ltd. no CRD number reported via Bean Capital Limited |
| EDGAR ↗ | Jul 24, 2019 D File 021-344933 | $0 | $0 | $0 (est.) Issuer pays an annual management fee to the General Partner of the Issuer. | None listed on this filing |
| EDGAR ↗ | Feb 8, 2018 D File 021-305225 | $60,000 (est.) | $0 | $0 (est.) | Phoenix Financial Inc. BrokerCheck CRD 144403 ↗ |
| EDGAR ↗ | Jan 25, 2018 D File 021-304146 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 15, 2017 D File 021-292864 | $0 | $0 | $0 Issuer expects to use proceeds from the offering for among other things general corporate purposes which includes payment of salaries to executive officers. | None listed on this filing |
| EDGAR ↗ | Dec 30, 2016 D/A File 021-263556 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 28, 2015 D File 021-253961 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 22, 2015 D File 021-249881 | $0 | $0 | $0 (est.) Issuer pays an annual management fee to the General Partner of the Issuer. | None listed on this filing |
| EDGAR ↗ | Sep 10, 2015 D File 021-247388 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 25, 2015 D File 021-236631 | $640,500 | $0 | $0 | MTS Securities, LLC BrokerCheck CRD 104059 ↗ |
| EDGAR ↗ | Jul 9, 2014 D File 021-220643 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 14, 2014 D File 021-215479 | $544,558 | $0 | $0 (est.) | Chardan Capital Markets LLC BrokerCheck CRD 120128 ↗ |
| EDGAR ↗ | Sep 30, 2013 D File 021-203753 | $876,136 | $0 | $180,000 (est.) For back pay and reimbursement of expenses for officers. | MTS Securities, LLC BrokerCheck CRD 104059 ↗ Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗ |
| EDGAR ↗ | Aug 26, 2013 D File 021-201870 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 7, 2013 D File 021-191496 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 1, 2013 D File 021-191249 | $74,480 (est.) | $0 | $0 | Garden State Securities, Inc. BrokerCheck CRD 10083 ↗ |
| EDGAR ↗ | Dec 13, 2012 D/A File 021-188250 | $350,600 (est.) | $0 | $0 | Garden State Securities, Inc. BrokerCheck CRD 10083 ↗ |
| EDGAR ↗ | Apr 13, 2012 D File 021-176706 | $0 | $0 | $111,000 (est.) Amounts are for payment of salaries for executives | N/A no CRD number reported |
| EDGAR ↗ | Feb 9, 2012 D File 021-173185 | $102,851 (est.) | $0 | $85,000 (est.) | Aegis Capital Corp BrokerCheck CRD 15007 ↗ |
| EDGAR ↗ | Nov 1, 2011 D File 021-168093 | $91,125 | $0 | $0 | Rodman & Renshaw, LLC BrokerCheck CRD 16415 ↗ |
| EDGAR ↗ | Apr 1, 2011 D File 021-157753 | $0 | $8,026,875 (est.) | $0 | Jefferies and Company, Inc. BrokerCheck CRD 3247 ↗ |
| EDGAR ↗ | Mar 7, 2011 D/A File 021-156181 | $180,000 | $0 | $0 | Rodman & Renshaw, LLC BrokerCheck CRD 16415 ↗ |
| EDGAR ↗ | Mar 7, 2011 D/A File 021-156186 | $163,500 | $0 | $0 | Rodman & Renshaw, LLC BrokerCheck CRD 16415 ↗ |
| EDGAR ↗ | Mar 4, 2011 D File 021-156249 | $0 | $1,940,250 (est.) | $0 | Jefferies and Company, Inc. BrokerCheck CRD 3247 ↗ |
| EDGAR ↗ | Dec 6, 2010 D File 021-151410 | $0 | $207,694 | $0 | Jefferies and Company, Inc. BrokerCheck CRD 3247 ↗ |
| EDGAR ↗ | Nov 2, 2009 D File 021-70871-7N | $0 | $0 | $0 Proceeds from the offering will be used for general working capital. | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Orgenesis Inc. | Director | Mar 14, 2024 | D | $2,340,903 similar: $2,000,000–$19,999,994 | $2,340,903 | 46 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Ayala Pharmaceuticals, Inc. | Director Chair of Board | Nov 2, 2023 | D | $433,825 similar: $2,000,000–$19,999,994 | $433,825 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Orgenesis Inc. | Director | Sep 8, 2023 | D | $1,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Orgenesis Inc. | Director | Apr 14, 2022 | D | $14,800,000 similar: $2,000,000–$19,999,994 | $14,800,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Ayala Pharmaceuticals, Inc. | Director | Feb 11, 2022 | D | $4,750,000 similar: $2,000,000–$19,999,994 | $4,750,000 | 6 similar: 2–16 | $380,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Ayala Pharmaceuticals, Inc. | Director | Apr 28, 2021 | D | $11,093,521 similar: $2,000,000–$19,999,994 | $11,093,521 | 2 similar: 2–16 | $3,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Orgenesis Inc. | Executive Officer | Jan 29, 2020 | D | $9,240,000 similar: $2,000,000–$19,999,994 | $9,240,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Israel Biotech Fund II, L.P. group: Israel Biotech | Executive Officer Director of the General Partner of the General Partner | Jul 24, 2019 | D | $100,000,000 similar: $155,000–$5,250,000 | $65,000,000 | 44 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Orgenesis Inc. | Director | Feb 8, 2018 | D | Indefinite similar: $2,000,000–$19,999,994 | $1,200,000 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TAMIR BIOTECHNOLOGY, INC. | Director | Jan 25, 2018 | D | $1,500,000 similar: $2,000,000–$19,999,994 | $808,638 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galmed Pharmaceuticals Ltd. | Director | Aug 15, 2017 | D | $350,000 similar: $1,694,259–$16,000,000 | $100,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TAMIR BIOTECHNOLOGY, INC. | Director | Dec 30, 2016 | D/A | $1,722,476 similar: $2,000,000–$19,999,994 | $1,722,476 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TAMIR BIOTECHNOLOGY, INC. | Director | May 20, 2016 | D | $1,622,477 similar: $2,000,000–$19,999,994 | $1,524,978 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Orgenesis Inc. | Director | Dec 28, 2015 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $5,300,000 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Israel Biotech Fund I, L.P. group: Israel Biotech | Executive Officer Director of the general partner of the General Partner. | Oct 22, 2015 | D | $100,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | TAMIR BIOTECHNOLOGY, INC. | Director | Sep 10, 2015 | D | $800,000 similar: $2,000,000–$19,999,994 | $800,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CHAMPIONS ONCOLOGY, INC. | Director | Mar 25, 2015 | D | $14,000,000 similar: $2,000,000–$19,999,994 | $14,000,000 | 11 similar: 2–16 | $1 similar: $10,000–$50,000 |
| EDGAR ↗ | Orgenesis Inc. | Director | Jul 9, 2014 | D | $24,011 similar: $2,000,000–$14,000,000 | $24,011 | 1 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | IMMUNE PHARMACEUTICALS INC | Director | Apr 14, 2014 | D | $11,720,475 similar: $1,694,259–$16,000,000 | $11,720,475 | 42 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Akari Therapeutics Plc | Director | Sep 30, 2013 | D | $12,516,232 similar: $2,000,000–$14,000,000 | $12,516,232 | 18 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Y Labs, Inc. | Executive Officer, Director | Aug 26, 2013 | D | Indefinite | $1,000 | 1 | $10,000 |
| EDGAR ↗ | CHAMPIONS ONCOLOGY, INC. | Director | Feb 7, 2013 | D | $9,300,000 | $9,300,000 | 7 | $1 |
| EDGAR ↗ | Akari Therapeutics Plc | Director | Feb 1, 2013 | D | $10,000,000 | $931,000 | 7 | No minimum reported |
| EDGAR ↗ | Akari Therapeutics Plc | Director | Dec 13, 2012 | D/A | $1,503,000 | $1,503,000 | 20 | No minimum reported |
| EDGAR ↗ | Akari Therapeutics Plc | Director | Apr 13, 2012 | D | $1,100,000 | $0 | 2 | No minimum reported |
| EDGAR ↗ | Rosetta Genomics Ltd. | Director | Feb 9, 2012 | D | $1,750,000 | $1,750,000 | 1 | No minimum reported |
| EDGAR ↗ | Rosetta Genomics Ltd. | Director | Nov 1, 2011 | D | $1,948,501 | $1,518,751 | 21 | No minimum reported |
| EDGAR ↗ | K-V Pharmaceutical Co | Director | Apr 1, 2011 | D | $225,000,000 | $225,000,000 | 104 | $65,000 |
| EDGAR ↗ | Rosetta Genomics Ltd. | Director | Mar 7, 2011 | D/A | $2,725,000 | $2,725,000 | 13 | No minimum reported |
| EDGAR ↗ | Rosetta Genomics Ltd. | Director | Mar 7, 2011 | D/A | $2,500,000 | $2,500,000 | 17 | No minimum reported |
| EDGAR ↗ | K-V Pharmaceutical Co | Director | Mar 4, 2011 | D | $32,337,500 | $32,337,500 | 12 | $55,250 |
| EDGAR ↗ | Rosetta Genomics Ltd. | Director | Mar 3, 2011 | D | $2,725,000 | $2,725,000 | 13 | No minimum reported |
| EDGAR ↗ | Rosetta Genomics Ltd. | Director | Mar 3, 2011 | D | $2,500,000 | $2,500,000 | 17 | No minimum reported |
| EDGAR ↗ | K-V Pharmaceutical Co | Director | Dec 6, 2010 | D | $7,552,506 | $7,552,506 | 2 | $2,492,327 |
| EDGAR ↗ | TAMIR BIOTECHNOLOGY, INC. | Director | Nov 2, 2009 | D | $3,250,000 | $3,250,000 | 8 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pooled Investment Fund / 506(b) (83,801 filings); Pharmaceuticals / 506(b) (800 filings); Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as David Sidransky. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when David Sidransky appears on a new Form D, or when a court case or SEC action is matched to them. See plans →